Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
SCHEDULE 13G/A SCHEDULE 13G/A - Description View HTML
0000902664-25-003585.pdf
0000902664-25-003585.rtf
0000902664-25-003585.xls
SCHEDULE 13G/A SCHEDULE 13G/A - Description View HTML
0000080255-25-000589.pdf
0000080255-25-000589.rtf
0000080255-25-000589.xls
SCHEDULE 13G SCHEDULE 13G - Description View HTML
0000902664-25-003642.pdf
0000902664-25-003642.rtf
0000902664-25-003642.xls
15-12G 15-12G     View HTML
0001193125-25-166915.pdf
0001193125-25-166915.rtf
0001193125-25-166915.xls
EFFECT EFFECT View HTML
9999999995-25-002337.pdf
9999999995-25-002337.rtf
9999999995-25-002337.xls
SCHEDULE 13G SCHEDULE 13G - Description View HTML
0000902664-25-003076.pdf
0000902664-25-003076.rtf
0000902664-25-003076.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069383.pdf
0001104659-25-069383.rtf
0001104659-25-069383.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069379.pdf
0001104659-25-069379.rtf
0001104659-25-069379.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069378.pdf
0001104659-25-069378.rtf
0001104659-25-069378.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001104659-25-069382.pdf
0001104659-25-069382.rtf
0001104659-25-069382.xls